United Therapeutics Corporation
UTHR
$301.50
$2.080.70%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.24B | 1.21B | 1.20B | 1.11B | 1.07B |
| Total Depreciation and Amortization | 79.70M | 77.30M | 72.50M | 66.50M | 60.70M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 165.70M | 145.80M | 119.70M | 106.90M | 90.20M |
| Change in Net Operating Assets | -116.20M | -22.00M | -60.20M | -147.70M | -114.70M |
| Cash from Operations | 1.37B | 1.41B | 1.33B | 1.14B | 1.11B |
| Capital Expenditure | -300.30M | -283.20M | -246.50M | -238.50M | -227.70M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -89.20M | -89.20M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -402.40M | -199.60M | 663.70M | 910.20M | 700.90M |
| Cash from Investing | -702.70M | -482.80M | 417.20M | 582.50M | 384.00M |
| Total Debt Issued | 200.00M | -- | -- | -- | -- |
| Total Debt Repaid | -700.00M | -400.00M | -400.00M | -400.00M | -300.00M |
| Issuance of Common Stock | 101.50M | 135.50M | 160.10M | 141.80M | 113.30M |
| Repurchase of Common Stock | -21.20M | -16.10M | -1.01B | -1.01B | -1.01B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -11.50M | 0.00 | -2.70M | -2.70M | -2.70M |
| Cash from Financing | -431.20M | -280.60M | -1.25B | -1.27B | -1.20B |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 237.40M | 648.40M | 489.50M | 446.20M | 288.40M |